Abstract: Hereditary leiomyomatosis and renal cell carcinoma (HLRCC) is caused by germline mutations in the FH gene, and is associated with increased incidence of leiomyomas and a potentially aggressive variant of renal cell carcinoma (HLRCCassociated RCC). Absent immunohistochemical expression of fumarate hydratase (FH) has previously been used to diagnose HLRCC-associated RCC, but immunohistochemical staining of leiomyomas is not standard practice. We performed immunohistochemistry (IHC) on whole sections from consecutive cutaneous leiomyomas from our archives to evaluate for both FH and succinate dehydrogenase B expression, in addition to clinicopathologic data collection and review of all hematoxylin and eosin-stained slides for blinded morphologic evaluation of features reported to be seen in HLRCC-associated uterine leiomyomas. Ninety-six cutaneous leiomyomas from 87 patients were identified; 12 of these specimens were from 7 patients with documented HLRCC. FH expression by IHC was absent in 9 specimens and retained in 85 specimens; 2 cases were equivocal with minimal FH expression. Seven of the 9 absent expression specimens were from patients with HLRCC, as were both of the equivocal specimens. The overall sensitivity and specificity of absent FH expression in leiomyomas for detection of patients with HLRCC were 70.0% and 97.6%, respectively. Inclusion of cases classified as equivocal increased sensitivity to 75.0%. Succinate dehydrogenase B expression was retained in 95 specimens and equivocal in 1 specimen. None of the evaluated morphologic features showed any association with leiomyomas in HLRCC. Loss of FH immunohistochemical expression in cutaneous leiomyomas is a sensitive and specific marker for detection of HLRCC, thus suggesting a role for prospective FH IHC in patients with these tumors to screen for HLRCC.
H
ereditary leiomyomatosis and renal cell carcinoma (HLRCC), also known as Reed syndrome, is caused by a heterogenous collection of germline heterozygous mutations in the fumarate hydratase (FH) gene on chromosome 1q43. 1, 2 The FH enzyme is an integral component of the citric acid (Krebs) cycle, and normally catalyzes the conversion of fumarate into malate. Alterations in the FH enzyme lead to intracellular fumarate accumulation, resulting in marked disturbances of downstream cellular metabolism, epithelial to mesenchymal transition, and epigenetic modifications. 3 Phenotypically, HLRCC is associated with multiple cutaneous leiomyomas, uterine leiomyomas, and a potentially aggressive variant of renal cell carcinoma (RCC). 4, 5 This constellation of findings shows variable penetrance and was first described by Reed et al 6 in 1973 . Several studies characterizing HLRCC-associated RCC show these tumors to portend a poor prognosis with a high stage at presentation and high mortality rate, possibly representing a more aggressive disease course when compared with conventional clear cell renal cell carcinoma and other RCC. [7] [8] [9] The lifetime risk of renal cell carcinoma in HLRCC has been suggested to be as high as 20% to 30%, [10] [11] [12] however, when selection bias is removed, the actual penetrance of renal cancer in HLRCC may be closer to 10% to 15%. [13] [14] [15] Regardless of the discrepancies in reported incidence, the aggressive course of HLRCC-associated RCC has led to efforts to diagnose the syndrome early in life so that serial renal imaging can be used to detect renal cancers at an early stage. 14 Most often, the initial presenting neoplasm in a person with HLRCC is a leiomyoma of the uterus or skin, rather than renal cell carcinoma. In fact, the presence of multiple cutaneous leiomyomas is the most sensitive and specific phenotypic feature of HLRCC, and this finding justifies molecular genetic testing of an affected individual or family to detect germline FH mutations. 16, 17 Recently, the use of absent immunohistochemical expression of FH has been used to diagnose HLRCC-associated RCC, 9, 18 but immunohistochemical staining of leiomyomas of cutaneous, uterine, or other anatomic sites, is not yet standard practice. Furthermore, succinate dehydrogenase (SDH) is another citric acid cycle enzyme for which deficiency is associated with oncocytic renal tumors, [19] [20] [21] and its expression has not been described in cutaneous leiomyomas (with or without association with HLRCC). Therefore, we investigated the use of FH and SDH-B immunohistochemistry (IHC) staining of cutaneous leiomyomas to evaluate for the presence of familial cancer syndromes.
Some specific histopathologic features have been previously reported to be observed in HLRCC-associated RCC, such as prominent orangeophilic/eosinophilic nucleoli and perinucleolar halos. 7, 10, 18 These and other features such as increased cellularity, nuclear pleomorphism, and the presence of eosinophilic globular cytoplasmic inclusions, have been reported in uterine leiomyomas in HLRCC, and are shown in Figure 1 . [22] [23] [24] [25] These findings have not been similarly observed in cutaneous leiomyomas in HLRCC, 26, 27 but no blinded systematic evaluation of these morphologic features in a large cohort has been previously described. Therefore, we also sought to evaluate if these reported morphologic features or any others are present in cutaneous leiomyomas in HLRCC.
MATERIALS AND METHODS

Case Selection
With approval by the University of Michigan Institutional Review Board, the University of Michigan pathology database was searched for cutaneous leiomyomas diagnosed between 1995 and 2015, by keyword search of "cutaneous leiomyoma," "pilar leiomyoma," "piloleiomyoma," "angioleiomyoma," and "leiomyoma," with the last term restricted to assignment to the dermatopathology division. All available hematoxylin and eosin-stained slides with available paraffinembedded blocks were reexamined by subspecialty trained pathologists (with expertise in genitourinary pathology, gynecologic pathology, and dermatopathology) and relevant clinicopathologic data were recorded for each patient. Multiple specimens from the same patient were not excluded in an effort to perform blinded immunohistochemical and morphologic analysis of each cutaneous leiomyoma specimen without the introduction of bias from clinical data (data selection bias).
Immunohistochemistry
As both FH and SDH are citric acid (Krebs) cycle enzymes and renal tumors of patients with HLRCC might uncommonly demonstrate oncocytic morphology, 28 we performed IHC on consecutive whole tissue sections from each case to evaluate for both FH and SDH-B expression. Slides were stained on the Ventana Benchmark XT platform with the following commercially available antibodies: FH mouse monoclonal antibody, clone J-13
(1:100 dilution; Santa Cruz Biotechnology, Dallas, TX), and SDH-B mouse monoclonal antibody, clone 21A11AE7 (1:100 dilution; Abcam, Cambridge, MA). IHC slides were visually scored as retained, absent or equivocal, based on the expression of any cytoplasmic granular staining within the smooth muscle cells of the leiomyomas. External (positive and negative) immunohistochemical controls for both biomarkers were evaluated to ensure stain quality, and internal controls for each slide were similarly evaluated using skin adnexal or vascular structures as positive controls, and confirmed to be present in all absent expression cases. FH-deficient leiomyomas were defined as neoplasms which demonstrated completely absent FH expression with positive internal controls. IHC data were recorded in a blinded manner by 3 independent sources (C.S.C., S.L.S., and R.M.), with consensus reached in cases of discordance by blinded reevaluation performed by the same pathologists in concert.
Morphologic Evaluation
The leiomyomas were also evaluated for the presence of histologic features that have been previously proposed to be features of HLRCC-associated RCC, as well as HLRCCassociated uterine leiomyomas. These included prominent orangeophilic or eosinophilic nucleoli, perinucleolar halos, increased cellularity, nuclear pleomorphism (defined by multinucleation, or large, hyperchromatic or otherwise bizarre nuclear forms), and the presence of eosinophilic cytoplasmic globules (Fig. 1) . With the exception of cellularity, which was evaluated using a binary score (cellular vs. not cellular), each histologic feature was scored on a 3-point scale: absent to very rare (present in 0% to 1% of the tumor), focal (present in 1% to 10% of the tumor), and occasional to frequent (present in >10% of the tumor). The scoring criteria were provided to each evaluating pathologist (A.L. and M.P.C., with expertise in gynecologic pathology and dermatopathology, respectively) with photomicrograph examples of each. The evaluators were then asked to give an overall suspicion based on these criteria, also on a 3-point scale: no suspicion, low suspicion, and moderate to high suspicion for a cutaneous leiomyoma associated with HLRCC. The 3-point scale criteria were given a value from 0 to 2, and cellularity was given a value from 0 to 1. The overall tumor was ultimately assigned a morphologic suspicion score between 0 and 11 by summation of all scores.
FH Mutational Status
Mutational analysis was based on mutation testing ordered and interpreted during clinical practice, available within the patient's medical record. As such, mutational analysis methods slightly varied depending upon the independent laboratory at which they were performed, but analysis was subject to the quality control measures required for clinical genetic testing. Although the laboratory developed tests had slightly different characteristics, mutation analysis in each case included extraction of genomic DNA from peripheral whole blood samples followed by amplification of exons spanning the coding region of the fumarate hydratase gene (exons 0 to 9) by polymerase chain reaction, and then sequencing by an automated DNA sequencer and comparison with normal sequence. These were performed on peripheral blood samples to ensure that germline mutation status could be assessed, as a small but not insignificant proportion of uterine leiomyoma cases have been reported to acquire somatic FH mutations. [29] [30] [31] 
Statistical Analysis
Association between clinical features such as the presence of multiple cutaneous leiomyomas and FH mutations was examined by the Fisher exact test. Association between FH and SDH-B IHC staining and FH mutational status was similarly examined by the Fisher exact test. Difference in age at cutaneous leiomyoma diagnosis between patients with HLRCC and without HLRCC was calculated using a 2-tailed t test. A cutoff of P < 0.05 for statistical significance was used in all analyses. IHC sensitivities and specificities were calculated from data based on evaluation of each specimen as an independent event.
RESULTS
Clinical Features
Ninety-six consecutive specimens of cutaneous leiomyomas from 87 patients diagnosed between 1995 and 2015 were identified. Twelve of these specimens were from 7 patients (3 male and 4 female) with documented HLRCC; the remaining 84 specimens were from 80 patients without known HLRCC, including 4 reexcision specimens after biopsy. Syndrome diagnosis was proven by mutational analysis of the affected individual with associated clinicopathologic features in 6 cases ( Table 1) . The remaining patient deferred genetic testing but had a strong family history of HLRCC, although the precise germline mutation for that family was unavailable. Of clinical features, multiple leiomyomas were present in 6 of FIGURE 1. Images of hematoxylin and eosin-stained sections and corresponding FH IHC from a uterine leiomyoma of a 22-yearold patient where the leiomyoma was found to lack FH expression by IHC. A, Low-power magnification highlights the cellular nature of this leiomyoma. B and C, High-power magnifications highlight perinucleolar clearing with enlarged eosinophilic nucleoli (thin arrows), and cytoplasmic eosinophilic globules (thick arrows); these morphologic features are likely to be associated with uterine leiomyomas which lack FH expression. D, Cytoplasmic FH expression loss in the same uterine leiomyoma. Note the retained FH expression within vessels (thin arrow) serving as positive internal controls.
7 patients with HLRCC (86%), compared with none of the 80 patients without known HLRCC (P < 0.0001). Patients with HLRCC were significantly younger at diagnosis of cutaneous leiomyoma compared with patients without known HLRCC (30.2 vs. 51.8 y, P = 0.0011). A reported history of RCC in an immediate family member was present in 2 of 7 patients with HLRCC (28.6%) and none among the 80 individuals without known HLRCC (P = 0.0056). Hysterectomy or uterine myomectomy was performed for symptomatic leiomyomas in 3 of 4 women with HLRCC (28.6%) and 2 of 53 women without known HLRCC (P = 0.0013). The remaining woman with HLRCC was treated medically for symptomatic fibroids due to her young age (21 y). Renal imaging during initial work up for HLRCC showed renal cysts in 4 of 7 patients with HLRCC (57.1%), and none among patients without known HLRCC, although 1 patient did have a solid renal mass suspicious for RCC (P < 0.0001). These and additional clinicopathologic features of patients with HLRCC are shown in Table 2 .
IHC Results
FH expression was absent in 9 specimens and retained in 85 specimens (Figs. 2, 3) ; 2 specimens were classified as equivocal with minimal FH expression (Fig. 3) . Seven of the 9 absent expression specimens were from patients with HLRCC, as were both of the equivocal specimens ( Table 1 ). The overall sensitivity and specificity of absent FH expression in cutaneous leiomyoma specimens for patients with HLRCC in this cohort were 70.0% and 97.6%, respectively, when excluding equivocal staining. Inclusion of specimens classified as equivocal with those classified as absent increased sensitivity to 75.0%. SDH-B expression was retained in 95 specimens and was equivocal in 1 specimen. In leiomyomas with retained FH and SDH-B expression, the staining of whole tissue sections was found to be homogenous in neoplastic areas.
Morphologic Results
Of the histopathologic features evaluated, including prominent orangeophilic or eosinophilic nucleoli, perinucleolar halos, increased cellularity, nuclear pleomorphism (characterized by multinucleation, large hyperchromatic nuclei, or otherwise bizarre nuclear forms), and the presence of eosinophilic globules, none showed a significant correlation with patients with known HLRCC (Table 3 ). The morphologic suspicion score for lesions in patients with HLRCC, when averaged between the 2 reviewers, ranged from 0 to 6, with an overall average of 0.63. Only 2 of 12 cases (16.6%) were selected by either reviewer to be of low suspicion, and none were selected as moderate to high suspicion. In contrast, 32 of 84 cases (38%) from patients with no known HLRCC were selected as at least low suspicion, with overall scores in this cohort ranging from 0 to as high as 9. Overall, there was no correlation between the morphologic suspicion score and HLRCC, nor any individual morphologic feature. In fact, the average compiled feature score for lesions in patients with known HLRCC was slightly lower than the average score of patients with no known HLRCC (but not to a degree of statistical significance).
FH Mutations
Of the 6 patients with identified specific mutations, 4 were missense mutations, 1 was a nonsense mutation, and 1 was a 7 base-pair deletion leading to a frameshift (Table 1) . These mutations were distributed broadly across the exon regions of the gene. Of those HLRCC cases in this cohort with either equivocal or retained FH staining, all were in patients with missense 
DISCUSSION
Our study demonstrates that complete loss of FH IHC expression in cutaneous leiomyomas is a sensitive and highly specific marker for HLRCC in this cohort. Our study showed similar rates of complete loss of FH IHC expression in HLRCC-associated cutaneous leiomyomas compared with previous studies, 26, 27 and overall showed similar sensitivity, but much higher specificity. To our knowledge, no other study to date has examined the effectiveness of FH IHC in consecutive cases within a large cohort from a single institution. Our cohort much more closely simulates a prospective patient population, which could be triaged toward germline mutation genetic testing. Although the incidence of HLRCC is likely to be higher in the setting of in-house cases from a large tertiary care center with clinical referral services, one could reasonably expect to encounter biopsies of these tumors in this practice setting. Although it could be argued that the presence of multiple cutaneous leiomyomas in a single patient is sensitive enough to proceed directly to genetic testing, the privilege of an accurate and pertinent clinical history is not always provided, especially before the initial diagnosis of a cutaneous leiomyoma, and in situations where clinicians without extensive clinical experience with a rare genetic syndrome like HLRCC are performing the biopsy. This likely scenario further supports the prospective use of a routine, commercially available IHC stain in triaging all cutaneous leiomyomas, whether solitary or multiple. Furthermore, none of the 7 patients in our cohort carried a genetically confirmed diagnosis nor a clinical diagnosis of HLRCC before their initial cutaneous leiomyoma biopsy or excision.
Further investigation of the cases of cutaneous leiomyomas with weak but retained expression of FH by IHC demonstrates that expression appears to correlate with the type of FH mutation, as was observed in a previous study of uterine leiomyomas. 25 Some cases with missense mutations demonstrated equivocal or weak staining, while those cases from patients with nonsense or frameshift mutations showed definitive absence of FH expression. The observation of weak or equivocal staining in patients with missense mutations may be due to only slight alteration of the protein-antibody interaction. With the proposed use of FH IHC as a screening tool for triage to further genetic testing, it may be prudent to report cases with very weak or equivocal expression to clinicians for consideration of further clinical work up and/or germline testing, given the clinical implications of these findings.
SDH-B immunohistochemical expression was retained in all but 1 leiomyoma specimen, which was interpreted as equivocal staining due to the very weak, granular cytoplasmic staining identified. This finding demonstrates that known FH mutations identified by germline testing do not alter SDH-B protein expression, which is an intuitive finding as SDH lies directly upstream of fumarate hydratase in the citric acid cycle. However, it is interesting to note that mutations in both FH and SDH are associated with potentially aggressive renal tumors, presumably because of similar metabolic shifts from oxidative phosphorylation to aerobic glycolysis caused by the disruption of the citric acid cycle. The downstream effects of these shifts might promote renal oncogenesis by way of activation of the cellular hypoxia response pathway in the presence of adequate oxygen. 32 Also, FH mutations (linked to HLRCC-associated RCC) might generate renal tumors which uncommonly demonstrate a morphologic overlap with SDH deficient RCC. 28 Despite these shared/convergent metabolic cellular insults and possible morphologic overlap generated by FH and SDH deficiency, the association of cutaneous and uterine leiomyomas seems to be limited to FH mutations in our study, suggesting that widespread succination caused by reduced FH enzymatic activity could potentially play a role in the formation of leiomyomas in these patients. 33 Similar to previous studies, 26, 27 no significant correlation was found between the morphologic features evaluated (prominent orangeophilic/eosinophilic nucleoli, perinucleolar halos, increased cellularity, nuclear pleomorphism and the presence of eosinophilic globules) and the presence of known HLRCC or FH immunohistochemical expression status in our current cohort of patients.
The higher proportion of renal cyst abnormalities on renal imaging is potentially impacted by a difference in imaging frequency between patients with known HLRCC and those without known HLRCC, as many patients had no record of renal imaging. However, the proportion of patients in our study (4 /7 patients, 57.1%) is much higher than the recorded prevalence of the general population, which varies between 11.9% and 17.6% by ultrasound and 21% to 41% by computed tomographic scan. [34] [35] [36] [37] [38] [39] An association between HLRCC and increased incidence of renal cysts has been suggested previously, but the serial nature of renal imaging in patients with HLRCC potentially might introduce some reporting bias. 34 One of the primary purposes of confirming an early diagnosis of HLRCC in a proband is to initiate serial renal imaging to diagnose associated renal carcinomas at an early stage, and to initiate molecular genetic testing of asymptomatic at-risk relatives to allow for improved diagnostic certainty and early surveillance and treatment. The potential clinical significance for an early diagnosis of HLRCC cannot be overemphasized, considering the possibility of rapid evolution of renal tumors with a dismal prognosis in such patients. 18 We speculate that testing of cutaneous leiomyomas for FH immunohistochemical expression can provide an early trigger for further clinical workup and/or confirmatory molecular genetic testing in patients with potential HLRCC. This, in turn, is presumed to provide a survival benefit in such patients, though a realtime study to assess this benefit is difficult to design and carry out based on the rarity of this disease.
Strengths of this study include the consecutive nature of the clinical cohort at a large tertiary care academic center, allowing for a much broader and more comprehensive availability of clinical data than is usually available with consult material. Another strength of the study is the use of whole tissue sections, as well as the use of a currently commercially available antibody with easy potential applicability into a clinical immunohistochemical practice. Whole tissue sections permit a more robust protein expression assessment compared with tissue microarrays, especially when evaluating for the absence of immunohistochemical expression. Morphologic analysis in the current clinical cohort was blinded, systematic, and based on predefined evaluation criteria. Our conclusions further support the previous assertions that no known morphologic features can be relied upon to suggest underlying HLRCC in cutaneous leiomyomas.
Our patients with HLRCC in this cohort were documented to have germline mutations through direct blood samples or other appropriate germline mutation testing samples. A limitation of our study is that there was insufficient clinical suspicion for HLRCC for genetic testing to be performed in most patients in our cohort; therefore, they have unknown FH mutational status. This reduces the confidence of the definitive accuracy of our specificity, as the performance characteristics of the antibody are based on the assumption that those patients without multiple cutaneous or uterine leiomyomas are negative for FH mutations due to absence of other clinical stigmata coupled with the low prevalence of the disease. As such, since FH mutational status was not evaluted in many of the cases, and since little data is available regarding the effectiveness of serial renal imaging on mortality reduction in patients with HLRCC, we were not able to analyze cost-effectiveness of FH immunohistochemistry in this study. These are important factors to investigate in future studies. We were not able to evaluate the genomic cause of FH IHC expression loss in the 2 specimens from patients without known HLRCC (because of tissue unavailability), though the IHC stains on these specimens were repeated and results remained consistent. The observed sensitivity and specificity of loss of FH IHC expression for HLRCC in this cohort is based upon the assumption that these 2 patients without known HLRCC have a somatic and not germline FH loss. Another possible limitation is a likely reporting bias for clinical criteria such as family history of renal cancer or personal history of renal mass, as renal imaging and family cancer history is much more likely to be performed and documented in patients with HLRCC. However, despite this limitation, the use of almost entirely in-house cases in our study allowed for adequate family history documentation in the vast majority of cases.
In conclusion, FH immunohistochemical expression on whole tissue sections of our consecutive clinical cohort of cutaneous leiomyoma cases was fairly sensitive and highly specific for association with HLRCC. This immunohistochemical stain has potential to be used prospectively as a triage tool to prompt additional clinical work up and/or germline testing in patients with cutaneous leiomyomas, including those with first-time diagnosis of cutaneous leiomyomas, or in the common situation where significant clinical history is lacking. Performance of the antibody is better than previously reported when applied to a more realistic patient cohort, such as the one in our study using consecutive nonconsult cases. SDH-B immunohistochemical expression is unaltered in cutaneous leiomyomas associated with HLRCC in our study. Morphologic criteria observed in some uterine leiomyomas associated with HLRCC did not demonstrate any role in triaging further testing when applied to patients with cutaneous leiomyomas in this clinical cohort.
